公开(公告)号：CA2644679C

公开(公告)日：2013-12-03

申请号：CA2644679

申请日：2007-03-01

Applicant: STC UNM

Inventor： SMYTH HUGH ,  TRUMAN CHARLES RANDALL

IPC: A61M15/00

Abstract: The present invention comprises a dry powder inhaler (DPI) that uses a patient's inhalation flow to concentrate energy in an aeroelastic element for deaggregation and dispersion of a powder dose. The result is a DPI that delivers a dose independent of inspiratory abilities of the patient, solving a major problem of conventional DPIs. Increased tension on the aeroelastic element causes higher frequency vibrations and improved powder dispersion. The tension of the aeroelastic element can be modified prior to dispensing the DPI to the patient, allowing for individualization for single patients or groups of patients. In addition, the DPI has features that increase the turbulence of the airflow as it passes through the device, further increasing the dispersion and deaggregation of the powder. The DPI can hold a single dose or multiple doses. The powder doses can be dispensed directly onto the aeroelastic element, or may be in adjacent blister packaging.

公开(公告)号：HK1174662A1

公开(公告)日：2013-06-14

申请号：HK13101590

申请日：2013-02-05

Applicant: STC UNM

Inventor： PEABODY DAVID ,  CHACKERIAN BRYCE

IPC: C12N20060101 ,  A61K20060101 ,  C07K20060101

Abstract: The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on VLPs, especially MS2 VLPS over a wide range, from few than one-on average- to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of MS2 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates MS2 niRNA. Nucleic acid constructs are also disclosed which are useful in the expression of virus-like particles comprised of a coat polypeptide of PP7 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates PP7 mRNA.

公开(公告)号：AU2007224178B2

公开(公告)日：2013-03-07

申请号：AU2007224178

申请日：2007-03-01

Applicant: STC UNM

Inventor： TRUMAN CHARLES RANDALL ,  SMYTH HUGH

IPC: A61M15/00

Abstract: The present invention comprises a dry powder inhaler (DPI) that uses a patient's inhalation flow to concentrate energy in an aeroelastic element for deaggregation and dispersion of a powder dose. The result is a DPI that delivers a dose independent of inspiratory abilities of the patient, solving a major problem of conventional DPIs. Increased tension on the aeroelastic element causes higher frequency vibrations and improved powder dispersion. The tension of the aeroelastic element can be modified prior to dispensing the DPI to the patient, allowing for individualization for single patients or groups of patients. In addition, the DPI has features that increase the turbulence of the airflow as it passes through the device, further increasing the dispersion and deaggregation of the powder. The DPI can hold a single dose or multiple doses. The powder doses can be dispensed directly onto the aeroelastic element, or may be in adjacent blister packaging.

公开(公告)号：DE112011101133T5

公开(公告)日：2013-02-07

申请号：DE112011101133

申请日：2011-03-23

Applicant: DAIHATSU MOTOR CO LTD ,  STC UNM

Inventor： ASAZAWA KOICHIRO ,  YAMADA KOJI ,  TANAKA HIROHISA ,  YAMAMOTO KAZUYA ,  OLSON TIM ,  PYLYPENKO SVITLANA ,  ATANASSOV PLAMEN

IPC: H01M4/90 ,  H01M8/02 ,  H01M8/10

Abstract: In einer Brennstoffzelle, welche eine Elektrolytschicht, die einen Anionenbestandteil migrieren lässt, und eine brennstoffseitige Elektrode und eine sauerstoffseitige Elektrode, welche gegenüberliegend angeordnet sind, während sie die Elektrolytschicht sandwichartig anordnen, enthält, enthält die sauerstoffseitige Elektrode einen ersten Katalysator, welcher ein erstes Übergangsmetall und Polypyrrol enthält, und einen zweiten Katalysator, welcher ein zweites Übergangsmetall und eine Porphyrinring enthaltende Verbindung enthält, so dass das Mischungsverhältnis des ersten Katalysators bezogen auf 100 Massenanteile der Gesamtmenge des ersten Katalysators und des zweiten Katalysators mehr als 10 Massenanteile und unterhalb 90 Massenanteile ist.

公开(公告)号：CA2842306A1

公开(公告)日：2013-01-24

申请号：CA2842306

申请日：2012-07-18

Applicant: STC UNM

Inventor： ZEINELDEN REEMA

IPC: A61K9/16 ,  A61K9/14 ,  A61K9/22 ,  A61K47/30 ,  A61K47/48 ,  A61P35/00

Abstract: In one embodiment, the invention provides a new design of nanocarrier compositions that release their therapeutic load specifically at intraperitoneal cancers' site. These nanocarriers are administered intraperitoneally and comprise a plurality of porous nanoparticulates that (a) are loaded with one or more pharmaceutically-active agents alone or in combination with imaging agents thus providing a theranostic value and (b) that are encapsulated by and that support a lipid bilayer which is disrupted upon contact with a reactive oxygen species generated within the environment of the cancer. In other embodiments, the invention provides methods of treatment and pharmaceutical compositions comprising nanocarriers as described herein.

公开(公告)号：CA2834365A1

公开(公告)日：2012-11-01

申请号：CA2834365

申请日：2012-04-27

Applicant: SANDIA CORP ,  STC UNM

Inventor： BRINKER JEFFREY C ,  CARNES ERIC C ,  ASHLEY CARLEE ERIN

IPC: A61K9/16 ,  A61K38/17 ,  A61K47/30 ,  A61K47/48 ,  A61K48/00

Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

公开(公告)号：SG170094A1

公开(公告)日：2011-04-29

申请号：SG2011017258

申请日：2007-03-09

Applicant: STC UNM

Inventor： HERSEE STEPHEN M ,  WANG XIN ,  SUN XINYU

Abstract: Exemplary embodiments provide semiconductor devices including high-quality (i.e., defect free) group III-N nanowires and uniform group III-N nanowire arrays as well as their scalable processes for manufacturing, where the position, orientation, cross-sectional features, length and the crystallinity of each nanowire can be precisely controlled. A pulsed growth mode can be used to fabricate the disclosed group III-N nanowires and/or nanowire arrays providing a uniform length of about 10 nm to about 1000 microns with constant cross-sectional features including an exemplary diameter of about 10-1000 nm. In addition, high-quality GaN substrate structures can be formed by coalescing the plurality of GaN nanowires and/or nanowire arrays to facilitate the fabrication of visible LEDs and lasers. Furthermore, core- shell nanowire/MQW active structures can be formed by a core-shell growth on the nonpolar sidewalls of each nanowire.

公开(公告)号：DE69739170D1

公开(公告)日：2009-01-29

申请号：DE69739170

申请日：1997-10-03

Applicant: STC UNM

Inventor： SARTO GLORIA E ,  THOMPSON DONALD M

IPC: C12Q1/68 ,  G02B21/34

Abstract: A method of preparing flourescent in situ hybridization slides, comprising: providing a slide with a raised ring thereon; providing to the slide a DNA probe; providing to the slide cells and target DNA; providing to the slide a formamide-free mixture of 10%+/-2% by weight dextran sulfate and 15%-25% glycerol and 0.9% by weight salt or a solution of 10%+/-2% by weight dextran sulfate, 10-30% by volume formamide and 0.9% by weight salt; placing a coverglass on the ring; denaturing and hybridizing the slide; and performing a post-hybridization wash of the slide.

公开(公告)号：MX2008011275A

公开(公告)日：2008-11-25

申请号：MX2008011275

申请日：2007-03-09

Applicant: STC UNM

Inventor： HERSEE STEPHEN M ,  WANG XIN ,  SUN XINYU

IPC: H01L21/20

Abstract: Las modalidades ejemplares proporcionan dispositivos semiconductores que incluyen nanoalambres del grupo III-N de calidad alta (esto es, libre de defectos) y configuraciones del nanoalambre del grupo III-N uniforme así como sus procesos escalables para manufactura, donde la posición, orientación, características en sección transversal, longitud y cristalinidad de cada nanoalambre puede ser precisamente controlada. Un modo de crecimiento pulsado puede usarse para fabricar el nanoalambre del grupo III-N descrito y/o configuraciones del nanoalambre proporcionando una longitud uniforme de alrededor de 10 nm hasta alrededor de 1000 micrones con las características en sección transversal constantes incluyendo un diámetro ejemplar de alrededor de 10-1000 nm. Además, las estructuras del substrato GaN de calidad alta pueden formarse por coalescer la pluralidad del nanoalambre GaN y/o configuraciones del nanoalambre para facilitar la fabricación de los LEDs visibles o láseres. Además, las estructuras MW activas/nanoalambre de envolvente-núcleo pueden formarse por un crecimiento del envolvente-núcleo en las paredes laterales no polares de cada nanoalambre.

公开(公告)号：CA2670125A1

公开(公告)日：2008-05-15

申请号：CA2670125

申请日：2007-11-06

Applicant: STC UNM

Inventor： DU CLOS TERRY W ,  MOLD CAROLYN

IPC: A61K35/14 ,  A61K35/15 ,  A61K35/28

Abstract: The present invention relates to the use of suppressive macrophage or den dritic cells (activated with C-reactive protein or CRP-related compounds), f or the treatment of various disease states and conditions associated with im mune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE ), including lupus of the skin (discoid), systemic lupus of the joints, lung s and kidneys, hematological conditions including hemolytic anemia and low l ymphocyte counts, lymphadenopathy and CNS effects, including memory loss, se izures and psychosis, among numerous others as otherwise disclosed herein. I n another aspect of the invention, the reduction in the likelihood that a pa tient who is at risk for an outbreak of a disease state or condition associa ted with systemic lupus erythematosus or ITP will have an outbreak is an add itional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patien t. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP.